Viking Therapeutics Inc (NASDAQ:VKTX)
| 3.72 BATS BZX Real-Time Price As of 11:47am ET |  +0.13 / +3.63%Today’s Change | 2.02 Today|||52-Week Range 7.20 | -19.24% Year-to-Date |
Latest VKTX News | Press Releases
| Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised) Aug 05 / Zacks.com - Paid Partner Content | Intercept (ICPT) Earnings and Sales Miss Estimates in Q2 Aug 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 3.59 |
| Today’s open | 3.58 |
| Day’s range | 3.58 - 3.72 |
| Volume | 12,043 |
| Average volume (3 months) | 1,061,862 |
| Market cap | $262.3M |
Data as of 11:47am ET, 08/12/2022
Growth & Valuation
| Earnings growth (last year) | -30.94% |
| Earnings growth (this year) | -29.86% |
| Earnings growth (next 5 years) | +40.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.33 |
Competitors
| ---- | ||
| ACIUAC Immune SA | +0.19 | +5.85% |
| AADIAadi Bioscience Inc | +0.25 | +1.89% |
| AVEOAveo Pharmaceuticals... | +0.28 | +3.59% |
Data as of 11:47am ET, 08/12/2022
Financials
| Next reporting date | November 9, 2022 |
| EPS forecast (this quarter) | -$0.23 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$55.0M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
